Last reviewed · How we verify
Maraviroc (MVC)
Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells.
Maraviroc blocks the CCR5 chemokine receptor on the surface of CD4+ T cells, preventing HIV from entering and infecting these immune cells. Used for HIV-1 infection in treatment-experienced patients with CCR5-tropic virus, HIV-1 infection in treatment-naïve patients (in combination antiretroviral therapy).
At a glance
| Generic name | Maraviroc (MVC) |
|---|---|
| Also known as | Selzentry |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | CCR5 antagonist |
| Target | CCR5 (C-C chemokine receptor type 5) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Maraviroc is a selective antagonist of the CCR5 co-receptor, which HIV uses as an entry point into host cells alongside the primary CD4 receptor. By binding to CCR5, maraviroc prevents the virus from attaching to and entering CD4+ T cells, thereby blocking HIV infection. This mechanism is effective only against CCR5-tropic (R5) HIV strains, not X4-tropic variants that use the CXCR4 co-receptor.
Approved indications
- HIV-1 infection in treatment-experienced patients with CCR5-tropic virus
- HIV-1 infection in treatment-naïve patients (in combination antiretroviral therapy)
Common side effects
- Upper respiratory tract infection
- Cough
- Pyrexia
- Rash
- Abdominal pain
- Diarrhea
- Hepatotoxicity
Key clinical trials
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC). (PHASE2, PHASE3)
- Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen (PHASE2)
- Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients (PHASE2)
- Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults (PHASE2)
- Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) (PHASE4)
- Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women (PHASE2)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maraviroc (MVC) CI brief — competitive landscape report
- Maraviroc (MVC) updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI